← Back
Data updated: Mar 10, 2026
CELLTRION INC
ImmunologyOncologyGastroenterology
CELLTRION INC is a biotechnology company focused on Immunology, Oncology, Gastroenterology.
2016
Since
11
Drugs
-
Trials
20
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
AVTOZMA 2026-01-21
AVTOZMA 2026-01-14
OMLYCLO 2025-12-01
Manufacturing (CMC)
OSENVELT 2025-10-29
Efficacy
YUFLYMA 2025-10-16
EYDENZELT 2025-10-02
Type 3 - New Dosage Form
OSENVELT 2025-09-10
Labeling
INFLECTRA 2025-09-03
AVTOZMA 2025-07-29
TRUXIMA 2025-06-09
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Immunology 45%
5 drugs Phase 3: 11 Phase 1: 2
Oncology 27%
5 drugs Phase 3: 4
Gastroenterology 19%
4 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2
Ophthalmology 6%
1 drugs Phase 3: 1
Respiratory 4%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Oncology, Immunology, Ophthalmology, Respiratory
Roche big-pharma
Oncology, Ophthalmology, Immunology, Respiratory
Pfizer big-pharma
Oncology, Immunology, Gastroenterology
AbbVie big-pharma
Immunology, Oncology, Ophthalmology
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology, Respiratory